Osteonecrosis of the jaws associated with the use of yearly zoledronic acid: Report of 2 cases

Head and Neck

Volumn 35, Issue 1, 2013, Pages

  Lee, Jang Jaer ^a,b   Cheng, Shih Jung ^a,b   Wang, Yi Ping ^a,b   Jeng, Jiiang Huei ^a,b   Chiang, Chun Pin ^a,b   Kok, Sang Heng ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

BRONJ; dental implantation; osteoporosis; tooth extraction; yearly zoledronic acid

Indexed keywords

AMOXICILLIN; PARACETAMOL; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; DISEASE ASSOCIATION; DISEASE COURSE; ERYTHEMA; FEMALE; HUMAN; JAW OSTEONECROSIS; ORAL SURGERY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TOOTH EXTRACTION; TREATMENT RESPONSE;

AGED; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MANDIBLE; MAXILLA; MIDDLE AGED; OSTEOPOROSIS;

EID: 84871186945     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21758     Document Type: Article

References (23)

1. American College of Obstetricians and Gynecologists, Women's Health Care Physicians. Osteoporosis ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 50, January 2003. Obset Gynecol 2004; 103: 203-216.
2. Boccuzzi SJ, Folz SH, Omar MA, Kahler KH,. Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Osteoporosis Int 2005; 16 (Suppl 4): S35-S36.
3. Lo JC, Pressman AR, Omar MA, et al. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporosis Int 2006; 17: 922-928. (Pubitemid 43781507)
4. Penning-van Beest FJ, Erkens JA, Olson M, et al. Determinants of noncompliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin 2008; 24: 1337-1344. (Pubitemid 351741565)
5. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822. (Pubitemid 46698462)
6. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P,. A review of the literature on osteonecrosis of the jaw in patient with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007; 29: 1548-1558. (Pubitemid 47500128)
7. Rizzoli R, Burlet N, Cahall D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008; 42: 841-847.
8. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mebrotra B,. American Association of Oral and Maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws: 2009 update. J Oral Maxillofac Surg 2009; 67: 2-12.
9. Marx RE, Cillo JE, Ulloa JJ,. Oral bisphosphonates induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007; 65: 2397-2410. (Pubitemid 350100982)
10. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65: 369-376.
11. Grbic JT, Landesberg R, Lin SQ,. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 2008; 139: 32-40.
12. Marx RE,. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1117. (Pubitemid 37064711)
13. Migliorati C, A. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 2003; 21: 4253-4254.
14. Migliorati CA,. Article analysis and evaluation on "Low incidence of osteonecrosis of the jaw in postmenopausal women with osteoporosis taking zoledronic acid once yearly." J Evid Base Dent Pract 2009; 9: 13-15.
15. Woo SB, Hellstein JW, Kalmar JR,. Narrative review: bisphosphonates and osteonecrosis of the jaws [corrected]. Ann Intern Med 2006; 144: 753-761. (Pubitemid 46780635)
16. Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23: 826-836. (Pubitemid 351768801)
17. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23: 8580-8587. (Pubitemid 46211499)
18. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006; 24: 945-952. (Pubitemid 46638849)
19. Marx RE, Sawatari Y, Fortin M, Broumand V,. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63: 1567-1575. (Pubitemid 41525412)
20. Ruggiero S, Fralow J, Marx RE, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006; 2: 7-14.
21. Kunchur R, Need A, Hughes T, et al. Clinical investigation of C terminal cross linking telopeptide test in the prevention and management of bisphosphonate associated osteonecrosis of the jaws. J Oral Maxillofac Surg 2009; 67: 1167-1173.
22. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653-661. (Pubitemid 34815869)
23. McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL,. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol 2009; 114: 999-1007.